留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

免疫检查点抑制剂在复发/转移性鼻咽癌中的应用

高洋 孙昭 白春梅

高洋, 孙昭, 白春梅. 免疫检查点抑制剂在复发/转移性鼻咽癌中的应用[J]. 协和医学杂志, 2020, 11(5): 626-630. doi: 10.3969/j.issn.1674-9081.2020.05.021
引用本文: 高洋, 孙昭, 白春梅. 免疫检查点抑制剂在复发/转移性鼻咽癌中的应用[J]. 协和医学杂志, 2020, 11(5): 626-630. doi: 10.3969/j.issn.1674-9081.2020.05.021
Yang GAO, Zhao SUN, Chun-mei BAI. Application of Immune-checkpoint Inhibitors in Recurrent/Metastatic Nasopharyngeal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 626-630. doi: 10.3969/j.issn.1674-9081.2020.05.021
Citation: Yang GAO, Zhao SUN, Chun-mei BAI. Application of Immune-checkpoint Inhibitors in Recurrent/Metastatic Nasopharyngeal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 626-630. doi: 10.3969/j.issn.1674-9081.2020.05.021

免疫检查点抑制剂在复发/转移性鼻咽癌中的应用

doi: 10.3969/j.issn.1674-9081.2020.05.021
基金项目: 

中国医学科学院医学与健康科技创新工程 2016-12M-1-001

详细信息
    通讯作者:

    白春梅 电话:010-69158315,E-mail:baichunmei1964@163.com

  • 中图分类号: R246.5;R730.3

Application of Immune-checkpoint Inhibitors in Recurrent/Metastatic Nasopharyngeal Carcinoma

More Information
  • 摘要:

    鼻咽癌多与EB病毒感染相关,早期患者及时治疗后预后良好,但复发/转移性鼻咽癌治疗方式有限,预后不佳。近年来,免疫治疗在复发/转移性鼻咽癌中的研究十分广泛,其中免疫检查点抑制剂药物具有较好的疗效和良好的耐受性,引起临床广泛关注。程序性死亡受体-配体1(programmed death-ligand 1, PD-L1)表达状态、肿瘤突变负荷、循环EB病毒-DNA水平可能成为免疫检查点抑制剂疗效预测的生物标志物。本文将对免疫检查点抑制剂及其在复发/转移性鼻咽癌中的应用进行综述。

    作者贡献: 高洋查阅文献、撰写论文;孙昭指导、修改论 文;白春梅确立研究方向、提出修改意见。
    利益冲突  无
  • 表  1  正在进行中的鼻咽癌免疫检查点抑制剂相关临床研究汇总

    试验编号 肿瘤类别 肿瘤期别 干预措施 治疗地位 纳入人数(n) 试验阶段 目前状态
    NCT03558191 鼻咽癌 Ⅳ期 SHR-1210 三线及以上 155 Ⅱ期 招募中
    NCT03427827 鼻咽癌 Ⅲ~ⅣA期 SHR-1210 辅助治疗 400 Ⅲ期 招募中
    NCT03707509 鼻咽癌 Ⅳ期 吉西他滨+顺铂±SHR-1210 一线 250 Ⅲ期 招募中
    NCT03121716 鼻咽癌 Ⅳ期 SHR-1210+吉西他滨+顺铂 一线 20 Ⅰ期 开启,尚未招募
    NCT02875613 鼻咽癌 Ⅳ期 Avelumab 二线及以上 39 Ⅱ期 开启,尚未招募
    NCT02611960 鼻咽癌 Ⅳ期 Avelumab 二线及以上 39 Ⅱ期 开启,尚未招募
    NCT03769467 鼻咽癌 Ⅳ期 帕博利珠单克隆抗体+CTL (Tabelecleucel) 一线 60 Ⅰ/Ⅱ期 招募中
    NCT03082534 头颈部鳞癌、鼻咽癌等 Ⅳ期 帕博利珠单克隆抗体+西妥昔单抗 分一线/二线及以上亚组 83 Ⅱ期 招募中
    NCT02538510 头颈部肿瘤、唾液腺癌 Ⅳ期 帕博利珠单克隆抗体+伏立诺他 不限 49 Ⅰ/Ⅱ期 开启,尚未招募
    NCT03267498 鼻咽癌 Ⅱ~ⅣB期 纳武利尤单抗+顺铂+放疗 辅助治疗 40 Ⅱ期 招募中
    NCT03097939 鼻咽癌 Ⅳ期 纳武利尤单抗+伊匹单抗 一线或二线 40 Ⅱ期 招募中
    NCT02834013 鼻咽癌等多种罕见肿瘤 Ⅳ期 纳武利尤单克隆抗体+伊匹单抗 二线及以上 707 Ⅱ期 招募中
    NCT03619824 鼻咽癌 Ⅲ~ⅣA期 Sintilimab(IBI308)+吉西他滨+顺铂+放疗 诱导治疗 40 Ⅱ期 尚未招募
    NCT03700476 鼻咽癌 Ⅲ~ⅣA期 吉西他滨+顺铂+放疗±Sintilimab 诱导治疗 420 Ⅲ期 尚未招募
    NCT02605967 鼻咽癌 Ⅳ期 PDR001或化疗 二线及三线 122 Ⅱ期 招募中
    NCT03866967 鼻咽癌 Ⅳ期 AK105 三线及以上 153 Ⅱ期 招募中
    NCT03474640 晚期恶性肿瘤 Ⅳ期 Toripalimab 二线及以上 258 Ⅰ期 招募中
    NCT03752398 晚期实体瘤 Ⅳ期 XmAb®23104 二线及以上 144 Ⅰ期 尚未招募
    下载: 导出CSV
  • [1] Wei KR, Zheng RS, Zhang SW, et al. Nasopharyngeal carcinoma incidence and mortality in China, 2013[J]. Chin J Cancer, 2017,36:90. doi:  10.1186/s40880-017-0257-9
    [2] Chua MLK, Wee JTS, Hui EP, et al. Nasopharyngeal carcinoma[J]. Lancet,2016,387:1012-1024. doi:  10.1016/S0140-6736(15)00055-0
    [3] Ruuskanen M, Irjala H, Minn H, et al. Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma: A nationwide study in Finland[J]. Head Neck, 2019,41:349-357. http://www.zhangqiaokeyan.com/academic-journal-foreign-pmc_wiley-blackwell-online-open_thesis/040004934268.html
    [4] Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis[J]. Lancet Oncol,2015,16:645-655. doi:  10.1016/S1470-2045(15)70126-9
    [5] Yang L, Hong SD, Wang Y, et al. Development and External Validation of Nomograms for Predicting Survival in Nasopharyngeal Carcinoma Patients after Definitive Radiotherapy[J]. Sci Rep,2015,5:15638. doi:  10.1038/srep15638
    [6] Perri F, Della VSG, Caponigro F, et al. Management of recurrent nasopharyngeal carcinoma: current perspectives[J]. Onco Targets Ther,2019,12:1583-1591. doi:  10.2147/OTT.S188148
    [7] Le QT, Colevas AD, O'Sullivan B, et al. Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy[J]. J Natl Cancer Inst,2019,111:655-663. doi:  10.1093/jnci/djz044
    [8] Larbcharoensub N, Mahaprom K, Jiarpinitnun C, et al. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma[J]. Am J Clin Oncol, 2018,41:1204-1210. doi:  10.1097/COC.0000000000000449
    [9] Walker LSK, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses[J]. Nat Rev Immunol,2011,11:852-863. doi:  10.1038/nri3108
    [10] Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies[J]. Clin Cancer Res,2013,19:3462-3473. doi:  10.1158/1078-0432.CCR-13-0855
    [11] Fang WF, Zhang JW, Hong SD, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy[J]. Oncotarget,2014,5:12189-12202. doi:  10.18632/oncotarget.2608
    [12] Hsu MC, Hsiao JR, Chang KC, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma[J]. Mod Pathol,2010,23:1393-1403. doi:  10.1038/modpathol.2010.130
    [13] Xiao M, Qi F, Chen X, et al. Functional polymorphism of cytotoxic T-lymphocyte antigen 4 and nasopharyngeal carcinoma susceptibility in a Chinese population[J]. Int J Immunogenet, 2010,37:27-32. doi:  10.1111/j.1744-313X.2009.00888.x
    [14] Hsu C, Lee SH, Ejadi S, et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study[J]. J Clin Oncol,2017,35:4050-4056. doi:  10.1200/JCO.2017.73.3675
    [15] Ma B, Lim WT, Goh BC, et al. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)[J]. J Clin Oncol, 2018,36:1412-1418. doi:  10.1200/JCO.2017.77.0388
    [16] Fang WF, Yang YP, Ma YX, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol,2018,19:1338-1350. doi:  10.1016/S1470-2045(18)30495-9
    [17] Zhou YJ, Shi DB, Miao JJ, et al. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load[J]. Sci Rep,2017,7:43627. doi:  10.1038/srep43627
    [18] Fang WF, Zhang JW, Hong SD, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy[J]. Oncotarget, 2014,5:12189-12202. doi:  10.18632/oncotarget.2608
    [19] Ferris RL, Blumenschein GJ, Fayette J, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol,2018,81:45-51. doi:  10.1016/j.oraloncology.2018.04.008
    [20] Harrington KJ, Ferris RL, Blumenschein GJ, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial[J]. Lancet Oncol,2017,18:1104-1115. doi:  10.1016/S1470-2045(17)30421-7
    [21] Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016,17:956-965. doi:  10.1016/S1470-2045(16)30066-3
    [22] Liu MB, Han SJ, Zheng B, et al. Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States[J]. Cancer Manag Res,2019,11:9483-9493. doi:  10.2147/CMAR.S226243
    [23] Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembroli-zumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019,393:156-167. doi:  10.1016/S0140-6736(18)31999-8
    [24] Kim KY, Le QT, Yom SS, et al. Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients[J]. Int J Radiat Oncol Biol Phys,2017,98:996-1001. doi:  10.1016/j.ijrobp.2017.03.018
    [25] Wang WY, Lin TY, Twu CW, et al. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA[J]. Oncotarget,2016,7:42608-42616. http://www.ncbi.nlm.nih.gov/pubmed/27191654
    [26] Chan ATC, Hui EP, Ngan RKC, et al. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial[J]. J Clin Oncol,2018.doi: 10.1200/JCO.2018.77.7847.
    [27] Johnson DB, Frampton GM, Rioth MJ, et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade[J]. Cancer Immunol Res, 2016,4:959-967. doi:  10.1158/2326-6066.CIR-16-0143
    [28] Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science,2015,348:124-128. doi:  10.1126/science.aaa1348
    [29] Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial[J]. Lancet,2016,387:1909-1920. doi:  10.1016/S0140-6736(16)00561-4
    [30] Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types[J]. Nat Genet,2019,51:202-206. doi:  10.1038/s41588-018-0312-8
    [31] Brown SD, Warren RL, Gibb EA, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival[J]. Genome Res,2014,24:743-750. doi:  10.1101/gr.165985.113
    [32] Cesano A, Warren S. Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic[J]. Biomedicines,2018,6:14. doi:  10.3390/biomedicines6010014
  • 加载中
表(1)
计量
  • 文章访问数:  15
  • HTML全文浏览量:  3
  • PDF下载量:  8
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-01-10
  • 刊出日期:  2020-09-30

目录

    /

    返回文章
    返回